Article
Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.
Targeted oncology - 1 Feb 2017
Zhu Xiaoli, Bai Qianming, Lu Yongming, Qi Peng, Ding Jianhui, Wang Jialei, Zhou Xiaoyan
Abstract excerpt
BACKGROUND: The rare epidermal growth factor receptor (EGFR) mutation S768I has only been reported sporadically in patients with lung adenocarcinoma (AC). OBJECTIVE: This study aimed to investigate the prevalence of the S768I mutation in Chinese patients with lung AC and to retrospectively analyze the response of S768I mutants to tyrosine kinase inhibitors (TKIs). PATIENTS AND METHODS: A total of 6698 tissue...
Topics
- Adenocarcinoma
- Adenocarcinoma of Lung
- Aged
- Disease-Free Survival
- ErbB Receptors
- Female
- Humans
- Lung Neoplasms
- Middle Aged
- Mutation
- Protein Kinase Inhibitors
- Retrospective Studies